• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Charles River Laboratories launches CRISPR/Cas9 genome engineering technology

Charles River Laboratories launches CRISPR/Cas9 genome engineering technology

December 8, 2016
CenterWatch Staff

Charles River Laboratories International has launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology. Through a licensing arrangement with the Broad Institute of MIT and Harvard, Charles River can now offer custom in vivo and in vitrogenome editing. With this technology, Charles River will be able to develop more translational research models that will ultimately improve the efficiency and effectiveness of the drug discovery process.

“Utilizing the CRISPR/Cas9 platform, Charles River clients can work with a single provider for both the in vivo and in vitro phases of their research,” said Dr. Iva Morse, corporate vice president, chief scientific officer, Global Research Models and Services. “Working with us, clients can generate custom cell lines for early, exploratory discovery research, as well as generate in vivo pharmacology models, produce those models, and then use our Discovery Services offering to place those models in in vivo studies.”

Charles River has developed partnerships with three key groups globally for in vivo model creation services. In North America, the company is partnering with Mirimus, a leader in RNA interference technology specializing in the creation of customized genetically engineered mouse models. In Japan, Charles River is partnering with the Laboratory Animal Resource Center, University of Tsukuba, one of the country’s largest production institutes for genetically modified mice. In Europe, the company is aligned with Phenomin ICS, formerly the Institut Clinique de la Souris, a leader in mouse and rat creation and phenotyping and a key player in different strategic phenogenomics efforts, like the International Mouse Phenotyping Consortium.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing